Literature DB >> 24090606

Probucol and cilostazol exert a combinatorial anti-atherogenic effect in cholesterol-fed rabbits.

Yulong Chen1, Sihai Zhao, Bingqiao Huang, Yanli Wang, Yafeng Li, Ahmed Bilal Waqar, Ruihan Liu, Liang Bai, Jianglin Fan, Enqi Liu.   

Abstract

INTRODUCTION: Probucol (PB) and cilostazol (CZ) both exhibit anti-atherogenic effects. However, their combinatorial effects are unclear. This study was designed to investigate their combinatorial anti-atherogenic effect in cholesterol-fed rabbits.
MATERIALS AND METHODS: Rabbits were fed a cholesterol diet with PB or CZ alone or both PB and CZ for 16 weeks. The plasma levels of total cholesterol, LDL-cholesterol, HDL-cholesterol, C-reactive protein, superoxide dismutase, malondialdehyde, and nitric oxide (NO) were measured. The aortic atherosclerotic lesions were grossly and microscopically evaluated. Additionally, in vitro experiments were conducted using human umbilical vein endothelial cells. RESULTS AND
CONCLUSION: We found that the PB group and the PB+CZ group exhibited a reduction in the lesion areas (70% in the PB+CZ group, 56% in the PB group) compared with the vehicle group. However, although PB alone and PB+CZ led to a reduction in the lesion size, the histological analysis revealed that only PB+CZ significantly decreased the macrophage accumulation and smooth muscle cell proliferation in the lesions compared with the vehicle group. The plasma levels of total cholesterol in the PB+CZ group were decreased compared with the vehicle group, Moreover, PB+CZ exerted obvious anti-oxidant and anti-inflammatory effects. Interestingly, the PB+CZ treatment led to a marked increase in the levels of plasma NO. The in vitro experiments showed that the combinatorial treatment up-regulated the levels of NO and protein S-nitrosylation in endothelial cells treated with oxidized LDL. In summary, these results suggest that PB and CZ exert combinatorial anti-atherogenic effects.
© 2013. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Atherosclerosis; C-reactive protein; CRP; CZ; Cilostazol; HCD; HDL; HDL-C; HUVECs; LDL-C; MDA; MФ; NO; PB; Probucol; ROS; Rabbits; S-nitrosylation; SMC; SOD; TC; cilostazol; eNOS; endothelial nitric oxide synthase; high cholesterol diet; high-density lipoprotein cholesterol; high-density lipoproteins; human umbilical vein endothelial cells; low-density lipoprotein cholesterol; macrophages; malondialdehyde; nitric oxide; probucol; reactive oxygen species; smooth muscle cell; superoxide dismutase; total cholesterol

Mesh:

Substances:

Year:  2013        PMID: 24090606     DOI: 10.1016/j.thromres.2013.09.007

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  6 in total

1.  Comparison of the effects of three different Baccaurea angulata whole fruit juice doses on plasma, aorta and liver MDA levels, antioxidant enzymes and total antioxidant capacity.

Authors:  Muhammad Ibrahim; Maryam Abimbola Mikail; Idris Adewale Ahmed; Norazlanshah Hazali; Mohammad Syaiful Bahari Abdul Rasad; Radiah Abdul Ghani; Ridzwan Hashim; Solachuddin Jahuari Arief; Muhammad Lokman Md Isa; Samsul Draman
Journal:  Eur J Nutr       Date:  2017-05-17       Impact factor: 5.614

2.  Combination of cilostazol and probucol protected podocytes from lipopolysaccharide-induced injury by both anti-inflammatory and anti-oxidative mechanisms.

Authors:  Peng He; Harukiyo Kawamura; Minoru Takemoto; Yoshiro Maezawa; Takahiro Ishikawa; Ryoichi Ishibashi; Kenichi Sakamoto; Mayumi Shoji; Akiko Hattori; Masaya Yamaga; Shintaro Ide; Kana Ide; Aiko Hayashi; Hirotake Tokuyama; Kazuki Kobayashi; Koutaro Yokote
Journal:  J Nephrol       Date:  2016-12-22       Impact factor: 3.902

Review 3.  Rabbit models for the study of human atherosclerosis: from pathophysiological mechanisms to translational medicine.

Authors:  Jianglin Fan; Shuji Kitajima; Teruo Watanabe; Jie Xu; Jifeng Zhang; Enqi Liu; Y Eugene Chen
Journal:  Pharmacol Ther       Date:  2014-09-30       Impact factor: 12.310

4.  Cilostazol attenuates cardiac oxidative stress and inflammation in hypercholesterolemic rats.

Authors:  Rosane de Oliveira Lopes; Gabriel Ferreira Lima; Ana Beatriz Araújo Mendes; Lis Jappour Autran; Nikolas Cunha de Assis Pereira; Stephani Correia Brazão; Beatriz Alexandre-Santos; Eliete Dalla Corte Frantz; Christianne Brêtas Vieira Scaramello; Fernanda Carla Ferreira Brito; Nadia Alice Vieira Motta
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2022-04-06       Impact factor: 3.000

5.  Combined use of probucol and cilostazol with atorvastatin attenuates atherosclerosis in moderately hypercholesterolemic rabbits.

Authors:  Yanli Wang; Liang Bai; Yan Lin; Yulong Chen; Hua Guan; Ninghong Zhu; Yafeng Li; Shoucui Gao; Lijing Sun; Sihai Zhao; Jianglin Fan; Enqi Liu
Journal:  Lipids Health Dis       Date:  2015-07-29       Impact factor: 3.876

6.  Urotensin II promotes atherosclerosis in cholesterol-fed rabbits.

Authors:  Yafeng Li; Sihai Zhao; Yanli Wang; Yulong Chen; Yan Lin; Ninghong Zhu; Huadong Zheng; Min Wu; Daxing Cheng; Yandong Li; Liang Bai; Jianglin Fan; Enqi Liu
Journal:  PLoS One       Date:  2014-04-18       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.